SANOFI-AVENTIS (EPA:SAN) European Commission approves Aubagio® (teriflunomide) as the first oral MS therapy for first-line treatment of children and adolescents living with relapsing-remitting multiple sclerosis
Transparency directive : regulatory news
18/06/2021 15:45
SANOFI-AVENTIS's latest news
17/04/2024 07:00
12/04/2024 20:05
22/03/2024 07:30
15/03/2024 20:04
24/02/2024 15:51
23/02/2024 18:45
23/02/2024 07:00
22/02/2024 19:02
20/02/2024 23:40
15/02/2024 14:00
Other stories
19/04/2024 09:02
19/04/2024 07:11
19/04/2024 06:30
19/04/2024 09:50
19/04/2024 00:44
19/04/2024 06:33
19/04/2024 07:13
18/04/2024 19:33
18/04/2024 17:39
18/04/2024 18:16
18/04/2024 16:01
19/04/2024 01:40
18/04/2024 14:00
18/04/2024 22:54
19/04/2024 09:58
18/04/2024 21:26
19/04/2024 09:55
19/04/2024 03:53
18/04/2024 14:11
18/04/2024 19:44
18/04/2024 12:45
18/04/2024 17:53
19/04/2024 10:04
19/04/2024 01:26
18/04/2024 22:41
19/04/2024 01:46
19/04/2024 06:51
19/04/2024 08:30
19/04/2024 06:44
19/04/2024 05:03
18/04/2024 11:33
19/04/2024 06:00
18/04/2024 17:58
18/04/2024 11:30
18/04/2024 21:46
19/04/2024 03:30
18/04/2024 08:00
19/04/2024 07:05